- R&D 100 Awards
2014 R&D 100 Winner MDR-TB is a growing problem, estimated to kill 170,000 people annually and projected to infect more than two million people between 2011 and 2015. Janssen Research & Development LLC’s bedaquiline represents a significant scientific and public health advancement in the treatment of MDR-TB, as the first available medicine developed specifically for pulmonary MDR-TB treatment.
Bedaquiline was discovered in the 1990s and offers patients resistant to common TB drugs and their health care providers with a new treatment option. Current MDR-TB treatment is lengthy, typically consisting of a two-year regimen with up to six second-line drugs and, on average, less than a 50% treatment success rate globally. Bedaquiline brings new hope to MDR-TB patients as Phase II clinical trials have demonstrated that adding bedaquiline to current treatments decreased the time to culture conversion and improved culture conversion rates compared to placebo treatments.
Bedaquiline is a diarylquinoline antimycobacterial drug indicated as part of a combination therapy in adults (18 years or older) with pulmonary MDR-TB (a form of TB that is characterized by resistance to at least two of the four most powerful medicines in today’s standard treatment regimen).
Technology TB drug
DevelopersJanssen Research & Development LLC
The bedaquiline Development Team from Janssen Research & Development LLC Koen Andries, Principal Developer